Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Modell-Vorsorgeuntersuchung in zwei Betrieben (1976)
    Springer
    Journal of molecular medicine 54 (1976), S. 1169-1175 
    Details
    ISSN: 1432-1440
    Keywords: Medical screening preventive ; Laboratory screening ; Medical questionnaire ; Coronary disease ; Chronical bronchitis ; Diabetes mellitus ; Hypertension ; Peripheral circulatory troubles ; Vorsorge-Untersuchungen ; Laborscreening ; Med. Fragebogen ; Koronarerkrankungen ; Chron. Bronchitis ; Diabetes ; Hypertonie ; Periphere Durchblutungsstörungen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Ziel der Untersuchung war die Fahndung nach Koronarerkrankungen, chronischer Bronchitis, Diabetes mellitus, Hypertonie, peripheren Durchblutungsstörungen und Übergewicht in zwei Betrieben bei über 40jährigen arbeitsfähigen Personen. Typische Labortests, standardisierte kurze ärztliche Untersuchung und ein Fragebogen wurden eingesetzt. In einer 10%-Stichprobe wurde der Fragebogen durch ein Kontrollinterview wiederholt und die Hälfte des Serums per Post an das Labor gesandt neben dem Transport in gekühltem Behälter im Auto. Nach der Beschreibung der Durchführung der Untersuchungen und der klinisch-chemischen Verfahren wird eine Ergebnisübersicht gegeben. Insgesamt 2429 Probanden wurden untersucht, der Untersuchungsablauf in den Betrieben war gut organisiert, es entstanden keine Warteschlangen. Die Laborergebnisse werden nach Geschlecht, Alter und Ort mitgeteilt und ihre Zusammenhänge dargestellt. In knapp 70% der Männer und in etwas über 60% der Frauen wurde der Hausarzt benachrichtigt wegen mindestens einem verdächtigen Befund. Im einzelnen fand sich eine pathologische Glycoseausscheidung im Urin bei 14,7% der Untersuchten, eine Konzentrationserhöhung der Glucose (über 113 mg-%) bei 5,7% der Triglyceride (über 181 mg-%) bei 12,6%, des Cholesterins (über 264 mg-%) bei 15,4%, der Harnsäure (♂ über 7,7 mg-%, ♀ über 7,1 mg-%) bei 6,8%, des Kreatinins (über 1,3 mg-%) bei 6,4% und eine positive Sulfosalizylsäureprobe im Urin bei 2,2% der Untersuchten.
    Notes: Summary A screening study for coronary disease, chronical bronchitis, diabetes mellitus, hypertension, peripheral circulatory disturbance and overweight is described. 2429 persons aged over 40 years and working in two factories were studied. Typical laboratory tests, a short standardised examination by a physician and a questionnaire were used. In a 10% sample the questionnaire was repeated by an interview and the serum was sent to the laboratory not only by mail, but also by a special car transport in a cooled transport box. The results of the laboratory tests are presend according age, sex and factory. The family doctor had to be informed in nearly 70% of the men and about 60% of the women because of at least one suspicious symptom or sign. There was a pathological value of glucose in the urine in 14.7%, a rise of glucose in the blood (above 113 mg%) in 5.7%, of triglicerides (above 181 mg%) in 12.6%, of cholesterol (above 264 mg%) in 15.4%, of uric acid (♂ above 7.7 mg%, ♀ above 7.1 mg%) in 6.8%, of creatinine (above 1.3 mg%) in 6.4% and the presence of albumin in urine in 2.2% of the cases.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01469389
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued (1992)
    Springer
    European journal of clinical pharmacology 43 (1992), S. 357-363 
    Details
    ISSN: 1432-1041
    Keywords: Parkinson's disease ; Bromocriptine ; L-Dopa/benserazide ; early combination therapy ; long-term ; therapy ; mortality ; cardioprotection
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary L-Dopa supplemented by a peripheral decarboxylase inhibitor is considered the most potent therapeutic regimen prolonging active life in Parkinsonian patients. The long-term benefit of therapy is limited by adverse effects, such as dyskinesia and on-off phenomena, which can be mitigated by the concomitant administration of dopamine agonists, such as bromocriptine. In order to quantify the beneficial impact of early combination therapy, a controlled clinical trial (PRADO:PRA vi-del1 +DOpa) in patients with early Parkinson's disease was carried out, whereby L-Dopa monotherapy (in a fixed combination with benserazide (DoBe) was being compared with the same combination plus bromocriptine (DoBeBro). Patients were recruited and treated by 101 practising neurologists in the Federal Republic of Germany and in Hungary. 'Twenty seven clinical university centers cross-checked the patients at regular intervals. The trial started with 3 months of DoBe monotherapy (median dose of 375 mg L-Dopa for both randomized groups) followed by gradual substitution of DoBe by bromocriptine over 3 months in one of the groups (250 mg L-Dopa/10 mg bromocriptine). The target medication was maintained from study months 6 to 54. Parkinsonian symptoms were classified according to the Webster rating scale, the Hoehn and Yahr scale and the Zung Self-Rating Depression Scale. Adverse events and life status were checked at regular intervals. Special emphasis was given to motor performance tests. 587 patients (302 in the DoBe group and 285 in the DoBeBro group) were available for intention-to-treat analysis. Both groups were homogeneous at baseline in all observed parameters. DoBe and DoBeBro proved equi-effective in terms of antiparkinsonian activity after the substitution phase (P II) had been completed. In September 1991, after a median observation period on target medication of 38.4 months in the DoBe group and 40.1 months in the DoBeBro group, 18 versus 8 deaths had been registered. The Logrank test as well as analysis using the Cox model, both adjusted for age and sex, showedP-values of 0.018 and 0.021, respectively. The mortality risk associated with L-Dopa therapy was reduced by more than 50 % by its combination with bromocriptine. The study was terminated due to this difference in mortality. The causes of death were classified by the treating physicians and consultants. At the time of study termination 152 patients in the DoBe group and 121 in the DoBeBro group had already discontinued study medication. Of those further 26 patients had died by the date of the final evaluation, 15 on DoBe and 11 on DoBeBro. The results imply that combination therapy with bromocriptine should be preferred over L-Dopa monotherapy from the very beginning.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02220609
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...